By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...
Camizestrant with a CDK 4/6 inhibitor had a statistically significant and clinically meaningful improvement in PFS in ...
Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...
Topline results from the Phase III VERITAC-2 trial found that vepdegestrant provided a statistically significant and clinically meaningful improvement in progression-free survival in patients with ER+ ...
Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.
VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically ...
Tukysa (tucatinib) – an orally-active HER2 inhibitor – can be used in combination with anti-HER2 antibody trastuzumab and chemotherapy capecitabine in patients treated with two prior anti-HER2 ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback